Samedan Ltd Pharmaceutical Publishers


Advanced search

--> Publications European Pharmaceutical Contractor European Biopharmaceutical Review International Clinical Trials Pharmaceutical Manufacturing and Packing Sourcer Innovations in Pharmaceutical Technology Subscribe Online Conferences White Papers Samedan app Pharmaceutical Directory Industry Events Calendar News and Press Releases Employment Opportunities Advertising with us Contact Us

home > ebr

PUBLICATIONS

European Biopharmaceutical Review

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.

With editorial consisting of in-depth articles, case studies, meetings, and report reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focusses on geographic or therapeutic territories.

For further information please contact:
Advertising Simon Caplan	Editorial Vanessa Kintu

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for phones and tablets. You can download issues for offline reading, and our archives go as far back as 2008! Download for free on the App Store, GooglePlay, or Amazon.

Click here to view the digital version of EBR

	Subscribe
	Current Issue
	Archives
	Media Info
	Our Clients

Featured in this issue

Features

Antibiotic Resistance

Fighting the Global Threat

DAs antibiotic resistance continues to plague the healthcare industry, Adrian Fellows at AGA Nanotech urges companies to unite and educate

Neurodegenerative Diseases

Systems Medicine and Drug Repurposing

An Answerable Challenge

Neurodegeneration and neurological disorders as a whole could be considered as the main cause of disability-adjusted years. Dr Hermann Mucke at H.M. Pharma Consultancy encourages the exploration of new drug combinations to drive treatment of such diseases.

Features

The Cancer Problem

Closer to the Cure

Christian Rommel at Roche advises companies to refrain from treating every step forward in cancer research as a potential cure. Rather, scientists should accept that finding a cure will be a more difficult journey than anticipated.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd

Published quarterly in
January, April,
July, and October

Widgets Magazine

Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

All events >>

News and Press Releases

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market explored ahead of CPhI MEA

Saudi Arabia’s pharmaceutical market expected to grow at a CAGR of 5.5% until 2023. Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth
More info >>

All releases >>

Air Transport Publications

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

All white papers >>